All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Frontline Firmonertinib Generates Durable Efficacy in EGFR PACC–Mutant NSCLC

June 26th 2025

Firmonertinib produced durable responses in the first line treatment of patients with non–small cell lung cancer harboring EGFR PACC mutations.

Gene Mutation Could Be Target for ‘Ultrapersonalized’ Therapies in Colon Cancer

June 26th 2025

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene that may play an important role in colon cancer.

Satri-Cel NDA Gets Go-Ahead From NMPA in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer

June 26th 2025

The NMPA of China has accepted the new drug application for satricabtagene autoleucel in pretreated gastric/GEJ cancer.

FDA Approves Illuccix Gallium Ga-68 Gozetotide Injection for Pre-Taxane Radioligand Therapy in mCRPC

June 26th 2025

Gallium Ga-68 gozetotide injection is now indicated for use in PET imaging patient selection for radioligand therapy in the pre-taxane setting for mCRPC.

Ongoing Trials Aim to Remove Carboplatin from TCHP and Reduce Treatment Cycles in HER2+ Breast Cancer

June 26th 2025

As the HER2-positive breast cancer landscape continues to evolve, the omission of carboplatin in TCHP could drive significant change.

Quizartinib Plus Chemotherapy Shows Strong Activity in FLT3-ITD–Positive, NPM1-Mutated AML

June 26th 2025

FLT3-ITD positivity plus mutations in NPM1 and epigenetic regulatory genes led to heightened efficacy of quizartinib plus chemotherapy in newly diagnosed AML.

Future of DLBCL Therapy Hinges on Optimal Use of CAR T-Cell Therapy, Bispecifics, and Other Novel Strategies

June 26th 2025

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer

June 25th 2025

Selinexor improved PFS, TFST, TSST, and PFS2 in TP53 wild-type advanced/recurrent endometrial cancer.

CHMP Offers Positive Opinion for Zanubrutinib Tablet Formulation in B-Cell Malignancies

June 25th 2025

The EMA’s CHMP has recommended the approval of zanubrutinib tablets for B-cell malignancies.

Rusfertide Significantly Reduces Therapeutic Phlebotomy Necessity in Polycythemia Vera

June 25th 2025

Andrew Kuykendall, MD, discusses the utility of rusfertide in reducing therapeutic phlebotomy eligibility in patients with polycythemia vera.

Liquid Formulations Boost Treatment Adherence in Pediatric Patients With Cancer and Patients With Dysphagia

June 25th 2025

Kate Gasparini, PharmD, BCOP, BCPPS, discusses how liquid formulations of oral agents, including imatinib, can aid in the delivery of anticancer agents.

Yale Announces New Biomedical Imaging Institute

June 25th 2025

Yale School of Medicine announced the opening of the Yale Biomedical Imaging Institute, uniting imaging, clinical translation, and data science.

NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC

June 25th 2025

The NCCN Clinical Practice Guidelines in Oncology for NSCLC recommend taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC.

FDA Grants Priority Review to Revumenib for Relapsed/Refractory NPM1-Mutant AML

June 25th 2025

Revumenib’s sNDA has received priority review from the FDA for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia.

Novel Targeted, Chemo-Free, and Cellular Therapies Are Poised to Transform Treatment Paradigms in B-Cell Malignancies

June 25th 2025

Alexey Danilov, MD, PhD, shares key developments and areas of debate from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Neoadjuvant Vidutolimod Plus Pembrolizumab Elicits Responses and Is Safe in Stage III Melanoma

June 25th 2025

Ahmad Tarhini, MD, PhD, discusses key findings from the EA6194 trial and how these data support the continued investigation of vidutolimod in melanoma.

Indirect Comparison Shows Zanubrutinib Outperforms Acalabrutinib/Venetoclax in Frontline CLL

June 25th 2025

Talha Munir, MBChB, PhD, discusses findings from an Indirect comparative of zanubrutinib vs acalabrutinib plus venetoclax in treatment-naive CLL.

5-Year Analysis of KEYNOTE-564 Reinforces Role of Adjuvant Pembrolizumab as SOC in ccRCC

June 24th 2025

Naomi B. Haas, MD, delves into the KEYNOTE-564 trial and highlights the role of adjuvant pembrolizumab in clear cell renal cell carcinoma.

Additional Treatment Options Underscore the Need for Collaboration and Mutational Testing in GIST

June 24th 2025

Robin Jones MD, MBBS, MRCP, discusses the treatment landscape of GIST and how patients can be effectively treated in the community.

ZR2 Plus R-DHAP and Zanubrutinib Maintenance With/Without ASCT Displays Promising Efficacy in Newly Diagnosed MCL

June 24th 2025

R2 followed by R-DHAP led to an ORR of 93.3% in patients with newly diagnosed MCL.